Logotipo del repositorio
Logotipo del repositorio
 

Treatment patterns and outcomes of first lupus nephritis episode over 25 years in two Latin American cohorts

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorQuintana, Rosana
dc.contributor.authorHernandez, Lucia
dc.contributor.authorPons-Estel, Guillermo
dc.contributor.authorScolnik, Marina
dc.contributor.authorSubils, Gisela
dc.contributor.authorOtaduy, Cintia
dc.contributor.authorSaurit, Verónica
dc.contributor.authorArturi, Valeria
dc.contributor.authorBerbotto, Guillermo A.
dc.contributor.authorGonzalez Lucero, Luciana
dc.contributor.authorMario Kerzberg, Eduardo
dc.contributor.authorPerez, Nicolas
dc.contributor.authorNora Pisoni, Cecilia
dc.contributor.authorCrespo, Maria Elena
dc.contributor.authorMartinez Serventi, Joaquín
dc.contributor.authorO. S. Montandon, Ana Carolina
dc.contributor.authorMonticielo, Odirlei Andre
dc.contributor.authorAtaide Mariz, Henrique
dc.contributor.authorMendes Klumb, Evandro
dc.contributor.authorBorba, Eduardo F.
dc.contributor.authorParente Costa Seguro, Luciana
dc.contributor.authorTorres dos Reis-Neto, Edgard
dc.contributor.authorBonfa, Eloisa
dc.contributor.authorBondi Peralta, Alexis
dc.contributor.authorMimica, Milena
dc.contributor.authorAroca Martínez, Gustavo
dc.contributor.authorCadena Bonfanti, Andres
dc.contributor.authorCañas, Carlos A.
dc.contributor.authorQuintana-Lopez, Gerardo
dc.contributor.authorToro Gutierrez, Carlos Enrique
dc.contributor.authorMoreno Alvarez, Mario Javier
dc.contributor.authorSaavedra, Miguel Angel
dc.contributor.authorHernandez, Margarita Portela
dc.contributor.authorFragoso-Loyo, Hilda
dc.contributor.authorSilveira, Luis H.
dc.contributor.authorGarcía-Valladares, Ignacio
dc.contributor.authorAbud-Mendoza, Carlos
dc.contributor.authorEsquivel Valerio, Jorge A.
dc.contributor.authorLangjahr, Patricia
dc.contributor.authorPaats, Astrid
dc.contributor.authorMora-Trujillo, Claudia S
dc.contributor.authorUgarte-Gil, Manuel F.
dc.contributor.authorCalvo Quiroz, Armando
dc.contributor.authorMuñoz Louis, Roberto
dc.contributor.authorRebella, Martín
dc.contributor.authorDanza, Alvaro
dc.contributor.authorOrillion, Ashley
dc.contributor.authorKaryekar, Chetan
dc.contributor.authorZazzetti, Federico
dc.contributor.authorAlarcón, Graciela S.
dc.contributor.authorPons-Estel, Bernardo A.
dc.date.accessioned2026-05-04T23:00:57Z
dc.date.available2026-05-04T23:00:57Z
dc.date.issued2026
dc.description.abstractAbstract Objectives: To compare the treatments used for the first episode of lupus nephritis (LN) in two Latin American cohorts (historical and contemporary) over a 25-year period, and their associations with clinical outcomes. Methods: Patients with biopsy-confirmed first LN episode were classified as non-proliferative (class V) or proliferative (classes III/IV). Sociodemographic, clinical, and treatment variables were described. Propensity score matching was used to examine the associations with four outcomes: mortality, damage accrual (SDI), hospitalization, and end-stage renal disease (ESRD). Results: A total of 532 SLE patients were included: 362 from GLADEL 1.0 (historical cohort) and 170 from GLADEL 2.0. (contemporary). Compared to GLADEL 1.0, patients in GLADEL 2.0 received lower doses of oral glucocorticoids (GC), more frequently GC pulses and antimalarials but less frequently cyclophosphamide. An increase in the use of mycophenolate mofetil and other immunosuppressants was also observed. In the logistic regression models, SDI was associated with baseline SDI and GC pulses, whereas belonging to the GLADEL 2.0 was a protective factor. Mortality was associated with Mestizo ethnicity and partial health coverage; antimalarial was identified as a protective factor. Hospitalizations were associated with baseline SLEDAI and SDI, follow-up time, and lower educational level. Belonging to the GLADEL 2.0 cohort was protective against the occurrence of ESRD. Conclusions: Patients in the contemporary cohort benefited from advances in treatment strategies, with less cumulative damage and progression to ESRD, although mortality remained unchanged. These improvements likely reflect the increased use of newer therapies, more targeted approaches, in line with current treatment guidelines, and better access to specialized care.spa
dc.format.mimetypehttp
dc.identifier.citationQuintana R, Hernández L, Pons-Estel G, Scolnik M, Subils G, Cintia O, Saurit V, Arturi V, Berbotto GA, Lucero LG, Kerzberg EM, Perez N, Pisoni CN, Crespo ME, Serventi JM, Montandon ACOS, Monticielo OA, Mariz HA, Klumb EM, Borba EF, Costa Seguro LP, Torres Dos Reis-Neto E, Bonfa E, Peralta AB, Mimica M, Martínez GA, Bonfanti AC, Cañas CA, Quintana-Lopez G, Toro Gutiérrez CE, Moreno Alvarez MJ, Saavedra MÁ, Hernández MP, Fragoso-Loyo H, Silveira LH, García-Valladares I, Abud-Mendoza C, Esquivel Valerio JA, Langjahr P, Paats A, Mora-Trujillo CS, Ugarte-Gil MF, Quiroz AC, Louis RM, Rebella M, Danza Á, Orillion A, Karyekar C, Zazzetti F, Alarcón GS, Pons-Estel BA. Treatment patterns and outcomes of first lupus nephritis episode over 25 years in two Latin American cohorts. Lupus. 2026 Apr 28:9612033261445765. doi: 10.1177/09612033261445765. Epub ahead of print. PMID: 42047097.
dc.identifier.doihttps://doi.org/10.1177/09612033261445765
dc.identifier.issn1477-0962 (electrónico)
dc.identifier.issn0961-2033 (Impreso)
dc.identifier.urihttps://hdl.handle.net/20.500.12442/17628
dc.identifier.urlhttps://journals.sagepub.com/doi/full/10.1177/09612033261445765
dc.language.isoeng
dc.publisherSAGEspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectLupus erythematosus systemicspa
dc.subjectLupus nephritisspa
dc.subjectTreatmentspa
dc.subjectEpidemiologyspa
dc.subjectLatin Americanspa
dc.titleTreatment patterns and outcomes of first lupus nephritis episode over 25 years in two Latin American cohortsspa
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesFanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80(1): 14–25. https://doi.org/10.1136/ annrheumdis-2020-218272spa
dcterms.referencesMahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus 2020; 29(9): 1011–1020. https://doi.org/10.1177/ 0961203320932219spa
dcterms.referencesTektonidou MG, Dasgupta A and Ward MM. Risk of endstage renal disease in patients with lupus nephritis, 1971- 2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 2016; 68(6): 1432–1441. https://doi.org/10. 1002/art.39594spa
dcterms.referencesManingding E, Dall’Era M, Trupin L, et al. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California lupus surveillance project. Arthritis Care Res 2020; 72(5): 622–629. https://doi.org/10.1002/acr.23887spa
dcterms.referencesAlarcón GS, McGwin G Jr, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: profile. Lupus 2002; 11(2):95–101. https://doi.org/10.1191/0961203302lu155oaspa
dcterms.referencesPons-Estel GJ, Alarcón GS, Burgos PI, et al. Grupo Latino Americano de Estudio de Lupus (GLADEL). Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus 2013; 22(9): 899–907. https://doi. org/10.1177/0961203313496339spa
dcterms.referencesPons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)- Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis 2018; 77(11): 1549–1557. https:// doi.org/10.1136/annrheumdis-2018-213512spa
dcterms.referencesFanouriakis A, Kostopoulou M, Cheema K, et al. Update of the joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79(6):713–723. https://doi.org/10.1136/annrheumdis-2020-216924spa
dcterms.referencesFanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78(6): 736–745. https://doi.org/10.1136/annrheumdis-2019-215089spa
dcterms.referencesPons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception Quintana et al. 11 cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among Hispanics. Medicine (Baltim) 2004; 83(1): 1–17. https://doi.org/10.1097/01.md. 0000104742.42401.e2spa
dcterms.referencesTan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25(11): 1271–1277. https://doi.org/10. 1002/art.1780251101spa
dcterms.referencesGómez-Puerta JA, Pons-Estel GJ, Quintana R, et al. A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: launching the GLADEL 2.0 study group. Lupus 2021; 30(4): 630–640. https://doi.org/10.1177/ 0961203320988586spa
dcterms.referencesHochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(9): 1725. https:// doi.org/10.1002/art.1780400928spa
dcterms.referencesPetri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64(8): 2677–2686. https://doi.org/10. 1002/art.34473spa
dcterms.referencesBajema IM, Wilhelmus S, Alpers CE, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int 2018; 93(4): 789–796. https://doi. org/10.1016/j.kint.2017.11.023spa
dcterms.referencesGraffar M. A method of social classification of population samples. Courrier VI 1956; 6: 455–459.spa
dcterms.referencesGladman DD, Ibañez D and Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29(2): 288–291.spa
dcterms.referencesGladman D, Urowitz M, Fortin P, et al. Systemic lupus international collaborating clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol 1996; 23(11): 1953–1955.spa
dcterms.referencesSeldin MF, Qi L, Scherbarth HR, et al. Amerindian ancestry in Argentina is associated with increased risk for systemic lupus erythematosus. Gene Immun 2008; 9(4): 389–393. https://doi. org/10.1038/gene.2008.25spa
dcterms.referencesSeldin MF, Tian C, Shigeta R, et al. Argentine population genetic structure: large variance in Amerindian contribution. Am J Phys Anthropol 2007; 132(3): 455–462. https://doi.org/ 10.1002/ajpa.20534spa
dcterms.referencesPons-Estel GJ and Alarcón GS. Lupus in hispanics: a matter of serious concern. Cleve Clin J Med 2012; 79(12): 824–834. https://doi.org/10.3949/ccjm.79a.12048spa
dcterms.referencesRoberti J, Leslie HH, Doubova SV, et al. Inequalities in health system coverage and quality: a cross-sectional survey of four Latin American countries. Lancet Global Health 2024; 12(1): e145–e155. https://doi.org/10.1016/S2214-109X(23)00488-6spa
dcterms.referencesSanchez L, Johnson T, Williams S, et al. Identifying inequities in an urban Latin American population: a cross-sectional study in Australian primary health care. Aust J Prim Health 2020; 26(2): 140–146. https://doi.org/10.1071/ PY19049spa
dcterms.referencesWallace SP and Gutierrez VF. Equity of access to health care ´ for older adults in four major Latin American cities. Rev Panam Salud Public ´ 2005; 17(5-6): 394–409. https://doi.org/ 10.1590/s1020-49892005000500012spa
dcterms.referencesQuintana R, Pons-Estel GJ, Roberts K, et al. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multiethnic, multinational Latin American lupus cohort. Lupus 2020; 29(9): 1140–1145. https://doi.org/10.1177/ 0961203320935184spa
dcterms.referencesShinjo SK, Bonfa E, Wojdyla D, et al. Antimalarial treatment ´ May have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62(3): 855–862. https://doi.org/10.1002/ art.27300spa
dcterms.referencesPons-Estel GJ, Catoggio LJ, Cardiel MH, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus 2015; 24(6): 536–545. https://doi.org/10.1177/ 0961203314567753spa
dcterms.referencesFanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024; 83(1): 15–29. https://doi.org/10.1136/ard-2023-224762spa
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int 2024; 105(1S): S1–S69. https://doi.org/10.1016/j. kint.2023.09.002spa
dcterms.referencesPons-Estel GJ, Quintana R, Ugarte-Gil MF, et al. Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients. Lupus 2024; 33(13): 1492–1501. https://doi.org/10.1177/0961203324128355spa
dcterms.referencesPons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39(4): 257–268. https://doi.org/10.1016/j.semarthrit.2008.10.007spa
dcterms.referencesPons-Estel GJ, Saurit V, Alarcón GS, et al. The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus 2012; 21(13): 1397–1404. https://doi.org/10. 1177/0961203312458465spa
dcterms.referencesPimentel-Quiroz VR, Ugarte-Gil MF, Pons-Estel GJ, et al. Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Semin Arthritis Rheum 2017; 47(2): 199–203. https://doi.org/10. 1016/j.semarthrit.2017.01.012spa
dcterms.referencesAlarcón GS, Rodr´ıguez JL, Benavides G Jr, et al. Systemic lupus erythematosus in three ethnic groups. V. Acculturation, health-related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA cohort. LUMINA study group. Lupus in minority populations, nature versus nurture. Arthritis Care Res 1999; 12(4):267–276.spa
dcterms.referencesUribe AG, McGwin G Jr, Reveille JD, et al. What have we learned from a 10-year experience with the LUMINA (lupus in minorities; nature vs. nurture) cohort? Where are we heading? Autoimmun Rev 2004; 3(4): 321–329. https://doi. org/10.1016/j.autrev.2003.11.005spa
dcterms.referencesDuran S, Apte M and Alarcón GS; LUMINA and Study ´ Group. Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J Natl Med Assoc 2007; 99(10): 1196–1198.spa
dcterms.referencesAlarcón GS, Beasley TM, Roseman JM, et al. Ethnic disparities in health and disease: the need to account for ancestral admixture when estimating the genetic contribution to both (LUMINA XXVI). Lupus 2005; 14(10): 867–868. https://doi. org/10.1191/0961203305lu2184xxspa
dcterms.referencesGisca E, Duarte L, Farinha F, et al. Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology 2021; 60(4): 1814–1822. https://doi.org/10.1093/ rheumatology/keaa491spa
dcterms.referencesBartels-Peculis L, Sharma A, Edwards AM, et al. Treatment patterns and health care costs of lupus nephritis in a United States payer population. Open Access Rheumatol 2020; 12: 117–124. https://doi.org/10.2147/OARRR.S248750spa
dcterms.referencesWorld health organization. https://www.who.int/healthtopics/socialdeterminants-of-health#tab=tab_1spa
dcterms.referencesParodis I, Lanata C, Nikolopoulos D, et al. Reframing health disparities in SLE: a critical reassessment of racial and ethnic differences in lupus disease outcomes. Best Pract Res Clin Rheumatol 2023; 37(4): 101894. https://doi.org/10.1016/j. berh.2023.101894spa
dcterms.referencesFernandez M, Alarcón GS, Calvo-Al ´ en J, et al. A multiethnic, ´ multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57(4): 576–584. https://doi.org/10.1002/art.22672spa
dcterms.referencesDemas KL and Costenbader KH. Disparities in lupus care and outcomes. Curr Opin Rheumatol 2009; 21(2): 102–109. https://doi.org/10.1097/BOR.0b013e328323daadspa
dcterms.referencesWilliams JN, Drenkard C and Lim SS. The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus. Rheumatology 2023; 62(Suppl 1): i10–i14. https://doi.org/10.1093/ rheumatology/keac613spa
dcterms.referencesUgarte-Gil MF, Pons-Estel GJ, Molineros J, et al. Disease features and outcomes in United States lupus patients of Hispanic origin and their mestizo counterparts in Latin America: a commentary. Rheumatology 2016; 55(3): 436–440. https://doi.org/10.1093/rheumatology/kev280spa
dcterms.referencesHernandez Cruz B, Alonso F, Calvo Al ´ en J, et al. Differences ´ in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of hispanics: european Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus 2020; 29(1): 27–36. https:// doi.org/10.1177/0961203319889667spa
dcterms.referencesDima A, Jurcut C, Chasset F, et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 2022; 14: 1759720X211073001. https://doi.org/10.1177/ 1759720X211073001spa
dcterms.referencesCai T, Zhao J, Yang Y, et al. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: a systematic review and meta-analysis of cohort studies. Lupus 2022; 31(14): 1714–1725. https://doi.org/10.1177/09612033221129774spa
dcterms.referencesJin Z, Wang F, Pan W, et al. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. Rheumatology 2021; 60(4): 1774–1783. https://doi.org/10.1093/rheumatology/keaa485spa
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
651.16 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca